Q-omics provides the consensus-scored PSMC2P2 profile across patient tissues and cancer cell-line models. PSMC2P2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PSMC2P2 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, PSMC2P2 RNA expression shows 9,961 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where PSMC2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMC2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMC2P2 survival associations across molecular data types. PSMC2P2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMC2P2 RNA expression–survival associations across cancer types. High PSMC2P2 expression shows unfavorable associations in KIRC, UCEC, OV, READ and ACC, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PSMC2P2 RNA expression.
This table summarizes PSMC2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PSMC2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMC2P2 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in STAD. The KIRC box plot shows higher PSMC2P2 RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p < 0.001).
This table shows molecular features associated with PSMC2P2 in patient tissues and cancer cell lines. In patient samples, PSMC2P2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
